Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
Mammary cancers together with cancers of the skin account for about 60% of the total cancers occurring in dogs. The veterinary options for therapeutic management of canine mammary cancer are limited and prognosis for such patients is poor. In this study, we analyzed the functionality of the oncolytic vaccinia virus strain GLV-1h68 as a possible therapeutic agent for canine mammary cancer. Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the canine mammary adenoma cell line ZMTH3. Furthermore, after systemic administration this attenuated vaccinia virus strain primarily replicated in canine tumor xenografts in nude mice. The efficient tumor colonization process resulted in inhibition of tumor growth and drastic reduction of tumor size. This is the first report demonstrating that vaccinia virus is an effective tool for the therapy of canine mammary cancers, which might next be applied to dogs with breast tumors.
Gentschev
I
I
Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.
Stritzker
J
J
Hofmann
E
E
Weibel
S
S
Yu
Y A
YA
Chen
N
N
Zhang
Q
Q
Bullerdiek
J
J
Nolte
I
I
Szalay
A A
AA
D000236:Adenoma / Q000097:blood / Q000628:therapy* / Q000662:veterinary*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D004285:Dogs; D005260:Female; D000882:Haplorhini; D015674:Mammary Neoplasms, Animal / Q000097:blood / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology; D014616:Vaccinia virus / Q000502:physiology*; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
D000914:Antibodies, Viral